A dynamic Bayesian nonlinear mixed-effects model of HIV response incorporating medication adherence, drug resistance and covariates

Annals of Applied Statistics

Volumn 5, Issue 1, 2011, Pages 551-577

  Huang, Yangxin ^a   Wu, Hulin ^b   Holden Wiltse, Jeanne ^b   Acosta, Edward P ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c UNIVERSITY OF ALABAMA   (United States)

Author keywords

Bayesian mixed effects models; Confounding factors; HIV dynamics; Longitudinal data; MEMS adherence assessment; Time varying drug efficacy; Virus resistance

Indexed keywords

EID: 84870262204     PISSN: 19326157     EISSN: 19417330     Source Type: Journal    
DOI: 10.1214/10-AOAS376     Document Type: Article

References (55)

1. Acosta, E. P., Wu, H., Walawander, A., Eron, J., Pettinelli, C., Yu, S., Neath, D., Ferguson, E., Saah, A. J., Kuritzkes, D. R., Gerber, J. G., for the Adult ACTG 5055 Protocol Team (2004). Comparison of two indinavir/ritonavir regimens in treatment-experienced HIV-infected individuals. Journal of Acquired Immune Deficiency Syndromes 37 1358-1366.
2. Akaike, H. (1973). Information theory and an extension of the maximum likelihood principle. In 2nd International Symposium on Information Theory (B. N. Petrov and F. Csáki, eds.) 267-281. Akadémiai Kiadó, Budapest.
3. Arnsten, J. H., Demas, P. A., Farzadegan, H. et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin. Infect. Dis. 33 1417-1423.
4. Bonhoeffer, S., Lipsitch, M. and Levin, B. R. (1997). Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. USA 94 12106-12111.
5. Bonhoeffer, S., May, R. et al. (1997). Viral dynamics and drug therapy. Proc. Natl. Acad. Sci. USA 94 6971-6976.
6. Bova, C. A., Fennie, K. P., Knafl, G. J. et al. (2005). Use of electronic monitoring devices to measure antiretroviral adherence: Practical considerations. AIDS Behav. 9 103-110.
7. Carroll, R. J., Ruppert, D. and Stefanski, L. A. (1995). Measurement Error in Nonlinear Models. Chapman and Hall, London.
8. Cobelli, C., Lepschy, A. and Jacur, G. R. (1979). Identifiability of compartmental systems and related structural properties. Math. Biosci. 44 1-18.
9. Davidian, M. and Giltinan, D. M. (1995). Nonlinear Models for Repeated Measurement Data. Chapman and Hall, London.
10. Gabrielsson, J. and Weiner, D. (2000). Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Apotekarsocieteten, Stockholm.
11. Gamerman, D. (1997). Markov Chain Monte Carlo: Stochastic Simulation for Bayesian Inference. Chapman and Hall, London.
12. Gelfand, A. E. and Smith, A. F. M. (1990). Sampling-based approaches to calculating marginal densities. J. Amer. Statist. Assoc. 85 398-409.
13. Ghosh, P., Branco, M. D. and Chakraborty, H. (2007). Bivariate random effect model using skew normal distribution with application to HIV-RNA. Statist. Med. 26 1255-1267.
14. Gilks, W. R., Richardson, S. and Spiegelhalter, D. J., eds. (1995). Markov Chain Monte Carlo in Practice. Chapman and Hall, London.
15. Hammer, S. M., Vaida, F. et al. (2002). Dual vs single protease inhibitor therapy following antiretroviral treatment failure: A random trial. J. Amer. Med. Assoc. 288 169-180.
16. Han, C., Chaloner, K. and Perelson, A. S. (2002). Bayesian analysis of a population HIV dynamic model. In Case Studies in Bayesian Statistics (C. Gatsoiquiry, R. E. Kass, A. Carriquiry, A. Gelman, D. Higdon, D. K. Pauler and I. Verdinellinis, eds.) 6 223-237. Springer, New York.
17. Haubrich, R. H., Little, S. J., Currier, J. S. et al. (1999). The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologogic response. AIDS 13 1099-1107.
18. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M. and Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 123-126.
19. Huang, Y. and Dagne, G. (2010). Skew-normal Bayesian nonlinear mixed-effects models with application to AIDS studies. Statist. Med. 29 2384-2398.
20. Huang, Y., Holden-Wiltse, J., Rosenkranz, S. L., Eron, J. J., Hammer, S. M., Mellors, J. W. and Wu, H. (2008). Modeling adherence of protease inhibitors for prediction of virologic response in HIV-1 infected patients: Comparison between adherence measurements by MEMS and questionnaire. Technical report, Department of Epidemiology and Biostatistics, Univ. South Florida, Tampa, FL.
21. Huang, Y., Liu, D. and Wu, H. (2006). Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system. Biometrics 62 413-423.
22. Huang, Y., Rosenkranz, S. L. and Wu, H. (2003). Modeling HIV dynamics and antiviral responses with consideration of time-varying drug exposures, sensitivities and adherence. Math. Biosci. 184 165-186.
23. Huang, Y. and Wu, H. (2006). A Bayesian approach for estimating antiviral efficacy in HIV dynamic model. J. Appl. Statist. 33 155-174.
24. Ickovics, J. R. and Meisler, A. W. (1997). Adherence in AIDS clinical trial: A framework for clinical research and clinical care. J. Clin. Epid. 50 385-391.
25. IMSL MATH/LIBRARY (1994). FORTRAN Subroutines for Mathematical Applications, Vol. 2. Visual Numerics, Houston.
26. Kastrissios, H., Suarez, J. R., Katzenstein, D. et al. (1998). Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS 12 2295-2303.
27. Knafl, G. J., Fennie, K. P., Bova, C. et al. (2004). Electronic monitoring device event modeling on an individual-subject basis using adaptive Poisson regression. Statist. Med. 23 783-801.
28. Labbé, L. and Verotta, D. (2006). A nonlinear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients. J. Pharmacokinet. Pharmacodyn. 33 519-542.
29. Levine, A. J., Hinkin, C. H., Marion, S. et al. (2006). Adherence to antiretroviral medications in HIV: Differences in data collected via self-report and electronic monitoring. Health Psychol. 25 329-335.
30. Liu, H., Miller, L. G., Golin, C. E. et al. (2007). Repeated measures analyses of dose timing of antiretroviral medication and its relationship to HIV virologic outcomes. Statist. Med. 26 991-1007.
31. Molla, A., Korneyeva, M. et al. (1996). Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Medic. 2 760-766.
32. Notermans, D. W., Goudsmit, J., Danner, S. A. et al. (1998). Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS 12 1483-1490.
33. Nowak, M. A., Bonhoeffer, S., Clive, L., Balfe, P., Semple, M., Kaye, S., Tenant-Flowers, M. and Tedder, R. (1995). HIV results in the frame. Nature 375 193.
34. Nowak, M. A., Lloyd, A. et al. (1997). Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J. Virol. 71 7518-7525.
35. Nowak, M. A. and May, R. M. (2000). Virus Dynamics: Mathematical Principles of Immunology and Virology. Oxford Univ. Press, Oxford.
36. Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squler, C., Wagener, M. M. and Singh, N. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. J. Internal Med. 133 21-30.
37. Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M. and Ho, D. D. (1996). HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271 1582-1586.
38. Perelson, A. S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M. and Ho, D. D. (1997). Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387 188-191.
39. Perelson, A. S. and Nelson, P. W. (1999). Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev. 41 3-44.
40. Pfister, M., Labbe, L., Hammer, S. M., Mellors, J., Bennett, K. K., Rosenkranz, S. L. and Sheiner, L B. and AIDS Clinical Trial Group Protocol 398 Investigators (2003). Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrobial Agents and Chemoterapy 47 130-137.
41. Schwarz, G. (1978). Estimating the dimension of a model. Ann. Statist. 6 461-464.
42. Spiegelhalter, D. J., Best, N. G., Carlin, B. P. and van der Linde, A. (2002). Bayesian measures of model complexity and fit. J. Roy. Statist. Soc. Ser. B 64 583-639.
43. Stafford, M. A. et al. (2000). Modeling plasma virus concentration during primary HIV infection. J. Theoret. Biol. 203 285-301.
44. Verbeke, G. and Lesaffre, E. (1996). A linear mixed-effects model with heterogeneity in random-effects population. J. Amer. Statist. Assoc. 91 217-221.
45. Verotta, D. (2005). Models and estimation methods for clinical HIV-1 data. J. Comput. Appl. Math. 184 275-300.
46. Vrijens, B., Goetghebeur, E., de Klerk, E., Rode, R., Mayer, S. and Urquhart, J. (2005). Modeling the association between adherence and viral load in HIV-infected patients. Statist. Med. 24 2719-2731.
47. Wainberg, M. A. et al. (1996). Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substition in 3TC-resistant HIV-1 reverse transcriptase. AIDS 10(Suppl.), S3-S10.
48. Wakefield, J. C., Smith, A. F. M., Racine-Poon, A. and Gelfand, A. E. (1994). Bayesian analysis of linear and non-linear population models using the Gibbs sampler. Appl. Statist. 43 201-221.
49. Wakefield, J. C. (1996). The Bayesian analysis to population pharmacokinetic models. J. Amer. Statist. Assoc. 91 62-75.
50. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., Saag, M. S. and Shaw, G. M. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373 117-122.
51. Wu, H., Ding, A. A. and de Gruttola, V. (1998). Estimation of HIV dynamic parameters. Statist. Med. 17 2463-2485.
52. Wu, H. and Ding, A. A. (1999). Population HIV-1 dynamics in vivo: Applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 55 410-418.
53. Wu, H., Huang, Y. et al. (2005). Modeling antiretroviral response: Effects of drug potency, pharmacokinetics, adherence and drug resistance. Journal of Acquired Immune Deficiency Syndromes 39 272-283.
54. Wu, L. (2002). A joint model for nonlinear mixed-effects models with censoring and covariates measured with error, with application to AIDS studies. J. Amer. Statist. Assoc. 97 955-964.
55. Zhu, L. and Carlin, B. P. (2000). Comparing hierarchical models for spatio-temporally misaligned data using the deviance information criterion. Stat. Med. 19 2265-2278.